Halozyme Therapeutics (HALO)

P/S ratio as of November 2026 (TTM): 7.06

According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 81.8. At the end of 2023 the company had a P/S ratio of 5.89.

P/S ratio history for Halozyme Therapeutics from 2005 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	5.89	-49.48%
2022	11.7	-8.73%
2021	12.8	-40.81%
2020	21.6	74.46%
2019	12.4	-11.3%
2018	13.9	53.06%
2017	9.11	4.45%
2016	8.72	-46.96%
2015	16.4	2.11%
2014	16.1	-48.6%
2013	31.3	75.34%
2012	17.9	1.63%
2011	17.6	-69.93%
2010	58.5	48.53%
2009	39.4	-24.36%
2008	52.0	-64.3%
2007	146	-74.13%
2006	564	-33.42%
2005	847

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Johnson & Johnson JNJ	6.80	-3.58%	🇺🇸 USA
Pfizer PFE	2.63	-62.73%	🇺🇸 USA
Eli Lilly LLY	14.8	109.10%	🇺🇸 USA
Sanofi SNY	1.97	-72.08%	🇫🇷 France
Baxter BAX	1.18	-83.32%	🇺🇸 USA
MannKind Corp MNKD	3.46	-51.02%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Halozyme Therapeutics (HALO)

P/S ratio as of November 2026 (TTM): 7.06